Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)

Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)

Multiple sclerosis (MS) is a prevalent neurologic autoimmune disorder affecting two million people worldwide. Symptoms include gait abnormalities, perception and sensory losses, cranial nerve pathologies, pain, cognitive dysfunction, and emotional aberrancies. Traditional therapy includes corticoste...

Full description

Bibliographic Details
Main Authors: Amnon A. Berger, Emily R. Sottosanti, Ariel Winnick, Jonathan Izygon, Kevin Berardino, Elyse M. Cornett, Alan D. Kaye, Giustino Varrassi, Omar Viswanath, Ivan Urits
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Neurology International
Subjects:
autoimmune
corticosteroids
disease-modifying agents
CNS plaques
disability
Online Access:https://www.mdpi.com/2035-8377/13/2/22
id doaj-f81d90cd16ae4484a9f3a5fc2aa42bab
record_format Article
spelling doaj-f81d90cd16ae4484a9f3a5fc2aa42bab2021-06-01T00:28:51ZengMDPI AGNeurology International2035-83772021-05-01132220722310.3390/neurolint13020022Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)Amnon A. Berger0Emily R. Sottosanti1Ariel Winnick2Jonathan Izygon3Kevin Berardino4Elyse M. Cornett5Alan D. Kaye6Giustino Varrassi7Omar Viswanath8Ivan Urits9Beth Israel Deaconess Medical Center, Department of Anesthesiology, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA 02115, USABeth Israel Deaconess Medical Center, Department of Anesthesiology, Critical Care, and Pain Medicine, Harvard Medical School, Boston, MA 02115, USASoroka University Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva 8400100, IsraelSoroka University Medical Center and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva 8400100, IsraelSchool of Medicine, Georgetown University, Washington, DC 20007, USADepartment of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USADepartment of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USAPaolo Procacci Foundation, Via Tacito 7, 00193 Roma, ItalyDepartment of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USADepartment of Anesthesiology, Louisiana State University Health Shreveport, Shreveport, LA 71103, USAMultiple sclerosis (MS) is a prevalent neurologic autoimmune disorder affecting two million people worldwide. Symptoms include gait abnormalities, perception and sensory losses, cranial nerve pathologies, pain, cognitive dysfunction, and emotional aberrancies. Traditional therapy includes corticosteroids for the suppression of relapses and injectable interferons. Recently, several modern therapies—including antibody therapy and oral agents—were approved as disease-modifying agents. Monomethyl fumarate (MMF, Bafiertam) is a recent addition to the arsenal available in the fight against MS and appears to be well-tolerated, safe, and effective. In this paper, we review the evidence available regarding the use of monomethyl fumarate (Bafiertam) in the treatment of relapsing-remitting MS.https://www.mdpi.com/2035-8377/13/2/22autoimmunecorticosteroidsdisease-modifying agentsCNS plaquesdisability
collection DOAJ
language English
format Article
sources DOAJ
author Amnon A. Berger
Emily R. Sottosanti
Ariel Winnick
Jonathan Izygon
Kevin Berardino
Elyse M. Cornett
Alan D. Kaye
Giustino Varrassi
Omar Viswanath
Ivan Urits
spellingShingle Amnon A. Berger
Emily R. Sottosanti
Ariel Winnick
Jonathan Izygon
Kevin Berardino
Elyse M. Cornett
Alan D. Kaye
Giustino Varrassi
Omar Viswanath
Ivan Urits
Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)
Neurology International
autoimmune
corticosteroids
disease-modifying agents
CNS plaques
disability
author_facet Amnon A. Berger
Emily R. Sottosanti
Ariel Winnick
Jonathan Izygon
Kevin Berardino
Elyse M. Cornett
Alan D. Kaye
Giustino Varrassi
Omar Viswanath
Ivan Urits
author_sort Amnon A. Berger
title Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)
title_short Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)
title_full Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)
title_fullStr Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)
title_full_unstemmed Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS)
title_sort monomethyl fumarate (mmf, bafiertam) for the treatment of relapsing forms of multiple sclerosis (ms)
publisher MDPI AG
series Neurology International
issn 2035-8377
publishDate 2021-05-01
description Multiple sclerosis (MS) is a prevalent neurologic autoimmune disorder affecting two million people worldwide. Symptoms include gait abnormalities, perception and sensory losses, cranial nerve pathologies, pain, cognitive dysfunction, and emotional aberrancies. Traditional therapy includes corticosteroids for the suppression of relapses and injectable interferons. Recently, several modern therapies—including antibody therapy and oral agents—were approved as disease-modifying agents. Monomethyl fumarate (MMF, Bafiertam) is a recent addition to the arsenal available in the fight against MS and appears to be well-tolerated, safe, and effective. In this paper, we review the evidence available regarding the use of monomethyl fumarate (Bafiertam) in the treatment of relapsing-remitting MS.
topic autoimmune
corticosteroids
disease-modifying agents
CNS plaques
disability
url https://www.mdpi.com/2035-8377/13/2/22
work_keys_str_mv AT amnonaberger monomethylfumaratemmfbafiertamforthetreatmentofrelapsingformsofmultiplesclerosisms
AT emilyrsottosanti monomethylfumaratemmfbafiertamforthetreatmentofrelapsingformsofmultiplesclerosisms
AT arielwinnick monomethylfumaratemmfbafiertamforthetreatmentofrelapsingformsofmultiplesclerosisms
AT jonathanizygon monomethylfumaratemmfbafiertamforthetreatmentofrelapsingformsofmultiplesclerosisms
AT kevinberardino monomethylfumaratemmfbafiertamforthetreatmentofrelapsingformsofmultiplesclerosisms
AT elysemcornett monomethylfumaratemmfbafiertamforthetreatmentofrelapsingformsofmultiplesclerosisms
AT alandkaye monomethylfumaratemmfbafiertamforthetreatmentofrelapsingformsofmultiplesclerosisms
AT giustinovarrassi monomethylfumaratemmfbafiertamforthetreatmentofrelapsingformsofmultiplesclerosisms
AT omarviswanath monomethylfumaratemmfbafiertamforthetreatmentofrelapsingformsofmultiplesclerosisms
AT ivanurits monomethylfumaratemmfbafiertamforthetreatmentofrelapsingformsofmultiplesclerosisms
_version_ 1721414803685113856

Similar Items